- Web Documents
- One Pagers
- Critical Care
- Fever in 88%
- Fatigue in 38%
- Dry cough in 67%
- Myalgias in 14.9%
- Dyspnea in 18.7%
- Sore Throat
- Gastrointestinal Symptoms
- A patient with acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath) AND with no other aetiology that fully explains the clinical presentation AND with a history of travel or residence in a country/area reporting local or community transmission* during the 14 days prior to symptom onset;
- OR A patient with any acute respiratory illness AND having been in close contact with a confirmed or probable COVID-19 case in the last 14 days prior to onset of symptoms;
- OR A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease (e.g., cough, fever, shortness breath)) AND requiring hospital isation (SARI) AND with no other aetiology that fully explains the clinical presentation.
- White blood cell count can vary. It does not provide accurate information about COVID-19.
- Leukopenia, leukocytosis, and lymphopenia have been reported.
- Lymphopenia is more common, seen in more than 80% of patients
- Mild thrombocytopenia is commonly seen. However thrombocytopenia is considered as a poor prognostic sign.
- Elevation can predict poor prognosis
- Initially normal, increased in ICU patients later
- Seems to track with disease severity and prognosis
- In patients suffering from with severe respiratory failure with a normal CRP level an alternative diagnosis should always be sought
- Oropharyngeal - (Aptima Swabs and MCS swabs)
- If initial testing is negative but the suspicion for COVID-19 remains, the WHO recom mends re-sampling and testing from multiple respiratory tract sites
- The findings on CXR are not specific, and in the initial phases of the disease the studies could be normal. The most common features include lobar/ multi-lobar / bilateral lung consolidation.
- Early stage (0-4 days after the onset of the symptoms), in which ground glass opacities (GGO) are frequent, with sub-pleural distribution and involving predominantly the lower lobes. Some patients in this stage could have a normal CT.
- Progressive stage (5-8 days after the onset of the symptoms), the findings usually evolved to rapidly involvement of the two lungs or multi-lobe distribution with GGO, crazy-paving and consolidation of airspaces.
- Peak stage (9-13 days after the onset of the symptoms), the consolidation becomes denser and it was present in almost all of the cases. Other finding was residual parenchymal bands.
- Absorption stage (>14 days after the onset of the symptoms), no crazy paving pattern was observed, the GGO could remain.
- Lung Ultrasound
- The findings include: Irregular pleural lines, sub-pleural areas of consolidation, areas of White lung and thick B lines . It is a tool that could be used at bed side avoiding the need for shifting infected patients to a Radiology suite.
- Learn more.
- All kinds of pulmonary function tests should be avoided among patients with a strong suspicion of upper or lower Respiratory tract infection.
- Any person diagnosed with SARS CoV 2 infection by means of laboratory testing at a government recommended testing laboratory.
- Anyone who has symptoms of fever and respiratory illness, and has a history of close contact of a person who has either been diagnosed as COVID-19, or has a history of travel to a COVID affected region within the last 14 days.
- Any health care worker with symptoms of fever and respiratory illness who has been involved directly in treating COVID- 19 patients, or has close contact with persons involved in treating COVID- 19 patients during the last 14 days.